First successes in the development of a gene therapy for incurable LAMA2-related muscular dystrophy

Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal ...
Business Wire

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT ...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
Mirage News

Gene Therapy Breakthroughs for Incurable Muscle Disease

Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal muscle disease in ...
WNCT

Sarcomatrix Renews EU Orphan Drug Status for LAMA2-RD and Expands Research into Duchenne Muscular Dystrophy Treatment

The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy. We are excited to have renewed our EU Orphan Drug ...
WAVY-TV

Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program

RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies ...